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Abstract: The natural history of asthma appears to be driven primarily by the timing and dura-
tion of viral respiratory infections. From the very high rate of infections in childhood, to the 
more sporadic pattern seen in adults, the cycle of acute injury followed by an inefficient repair 
process helps explain the clinical patterns of asthma severity currently recognized by asthma 
guidelines. Why the asthmatic host responds to viral injury in a particular way is largely a mystery 
and the subject of intense investigation. The role of viruses in asthma extends not just to inter-
mittent but to persistent disease, and to both the atopic as well as nonatopic phenotypes. Future 
therapeutic strategies should include primary prevention via the development of antiviral innate 
immunity-enhancing vaccines, as well as secondary prevention via the use of antiviral agents, 
or immunomodulators designed to boost the antiviral response or interrupt the   proinflammatory 
cascade.
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Introduction
In the last few years, there has been a shift in interest within the asthma community from 
focusing on what features all asthmatics have in common, to the differences that set 
them apart.1 We now speak routinely of asthma as a heterogeneous disease which can be 
categorized in various ways based on such characteristics as demographics; epidemio-
logy; natural history; histopathology; clinical manifestations; and response to therapy. 
However, some of the most important advances made recently in the characterization 
of asthma syndromes paint a picture of a common underlying etiology to at least the 
most prevalent form of the disease in children and perhaps in many adults.
Discussion
Viral asthma, primarily human rhinovirus-induced (HRV), is by far the most common 
form of active disease in children, accounting for over 80% of acute exacerbations2 
and the majority of hospitalizations and clinic visits. In young infants aged under   
2 years, winter viral respiratory infections play a major role in inducing the asthma 
phenotype.3
It appears to be less well recognized that HRV may also account for most cases of 
persistent asthma. Several recent studies have shed light on this topic and document that 
the effects of rhinovirus-triggered asthma attacks can be sustained for weeks to months 
following the initial upper respiratory infection (URI).4 Evidence of HRV persistence 
within the airways of patients5,6 and animal models,7 suggest that persistent asthma 
may also be a consequence of an initial or recurrent HRV-induced airway injury.8Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Based on these observations, and from a clinical perspective, 
a case can be made that at any point in time, most children and 
many adults with symptomatic asthma are   somewhere along 
a continuum of partial recovery or convalescence dating 
back to their most recent HRV infection, with the extent of 
recovery being primarily dependent on the robustness of 
their immune response to the viral injury. It is possible to 
conceptualize a cycle of injury-repair over time that would 
explain variations in clinical severity of the disease, modi-
fied somewhat by the effects of anti-inflammatory therapy. 
In some cases, the acute episode does lead to a brisk immune 
response with quick clearance of the virus and resolution of 
symptoms. This would be the clinical pattern we associate 
with so-called “intermittent” asthma or children that wheeze 
“only” during acute HRV URIs. In others, the innate and 
adaptative immune response to the initial URI is less than 
adequate and fails to either clear the virus or successfully 
repair the damage, which then leads to persist inflammation 
for many weeks or months, resulting in what has been termed 
a “prolonged exacerbation”.9 To the clinician who encounters 
this individual for the first time, this pattern would simply 
look like a “multi-trigger asthmatic” if a pre-schooler, or a 
“persistent” asthmatic if an adult.
A similar mechanism was proposed some years ago by 
Burrows10 to explain the association between frequency of 
acute exacerbations of chronic obstructive pulmonary disor-
der (COPD) and rate of decline in forced expiratory volume 
in 1 second (FEV1). Since then, several studies have docu-
mented both the primary role of HRV in acute exacerbations 
of COPD,11 and the relationship between exacerbations and 
rate of decline in lung function.12 Thus, the natural histories 
of asthma and COPD may both be linked in a sizable percent-
age of patients by the number and duration of HRV-induced 
exacerbations.
In more severe asthma, we are positing that viral injury 
leads to the phenotypic characteristics of persistent asthma. 
HRV infections tend to reoccur fairly frequently in the pedi-
atric population, particularly during the fall through spring 
months. A new URI arriving on top of a partially resolved 
previous infection could further overburden   antiviral defenses 
or find an already immunologically “primed” airway, lead-
ing to a shift in clinical pattern from a   mild-persistent to a 
more moderate or severe one. It has been our experience 
over many years of practice that when the fall outbreaks 
of HRV infections begin, it is typically not the first but the 
second or subsequent URIs that trigger the more serious 
asthma attacks. Based on recent experimental evidence on 
the mechanisms of viral-induced airway injury as mediated 
by pattern-recognition receptors,13 this “priming” effect of a 
viral infection could have significant implications for clini-
cal asthma.
Another fall out from this paradigm is that it helps to 
explain why most children with asthma (even fairly   significant 
persistent asthma) tend to “outgrow” the disease as they 
mature. It is well known that from childhood into early ado-
lescence, older children do not experience as many URIs as 
their younger counterparts. Not only does the number of acute 
exacerbations quickly diminish with age, but the intervening 
period of recovery available between attacks is also extended. 
Thus, fewer episodes with increased recovery time results 
in markedly improved asthma severity. There are also host 
factors, particularly in terms of viral immunity, that play a sig-
nificant role in modulating an individual patient’s long-term 
pattern, but the viral etiology of the disease remains primary. 
Thus the role of HRV infections should not be confined to 
acute exacerbations but also extended to explain chronicity 
of the disease. This is supported by recent evidence from 
animal models of experimental respiratory viral infections that 
suggest that airway remodeling and hyperresponsiveness can 
persist long after the virus is cleared from the airways.14
Whatever role other environmental factors such as aller-
gens play in the epidemiology of asthma appears trivial when 
faced with the accumulating evidence for the viral paradigm.15 
Even previous distinctions between atopic and nonatopic 
asthma seem less important in light of recent endobronchial 
biopsy evidence that fails to distinguish between the histologi-
cal presentation of atopic and   nonatopic asthma.16 Knowing 
that the host’s genotype (such as the ability to mount a robust 
Th2 allergic inflammatory response) plays a significant role 
in the viral response to injury, the primary role of HRV in 
driving the histopathology and clinical presentation in the 
large majority of asthmatics remains a valid consideration. 
This idea is further supported by recent advances in the biol-
ogy of antiviral Th2 immune responses. The concept of virus 
as allergens may well lead to more widespread recognition that 
in most asthmatics, whether atopic or nonatopic, the disease 
is closely linked to an infectious viral etiology.17
Implications
What are the implications of the role that viral infections 
play on the natural history of asthma for clinicians who treat 
asthma? First and foremost is the concept of asthma as a 
constantly evolving disease, driven by the natural history of 
viral-induced airway injury and repair. To the clinician, this 
translates to asthma being a dynamic disease consisting of 
periods of acute injury followed by periods of convalescence Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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that are of variable duration and intensity. This pattern can be 
further modulated by the effects of environmental “triggers” 
or by anti-inflammatory therapy. Predicting which pattern 
a particular patient will follow remains an elusive goal and 
should be the subject of further research. We believe that one 
of the most important questions that should be routinely asked 
of patients, that is not currently included in asthma control 
questionnaires, is “how long has it been since your last (URI-
triggered) exacerbation?” The answer can provide a useful 
index of how persistent the current exacerbation has been. 
The second most important question is “how many upper 
respiratory infections, with and without worsening asthma, 
have you experienced in the last ‘x’ number of months?” It is 
clear that in order to predict correctly outcomes in asthma 
we need clinical studies that focus on the clinical course and 
immunopathology of the recovery period or convalescent 
phase of acute asthma exacerbations.
It has recently been shown that anti-inflammatory therapy 
with inhaled corticosteroids has limited disease-modifying 
effects in asthma. One might well expect this to be the case 
in a primarily virus-driven condition. In a sense, viral asthma 
may be a disease of inadequate inflammation (less than effi-
cient immune response to viral infection) in contrast to “too 
much” (small airway) inflammation. Although its clinical 
manifestations clearly correlate with the extent of the inflam-
matory processes within the airways, this response clearly 
fails to confine the virus to the upper airways. Thus, we are 
probably more likely to find success in discovering new anti-
asthmatic therapies if we concentrate on antiviral agents, or 
ways to boost the immune response to viral spread, rather 
than on merely suppressing airway inflammation, whether 
broadly with corticosteroids or narrowly with single-path 
antagonists of the immune response.
Another key component of the concept of asthma as an 
acute/subacute viral disease has substantial implications for 
clinical trials. Asthma clinical trials, at least those performed 
for the purpose of gaining regulatory approval, are typically 
designed around the premise that asthmatics can be neatly 
classified within a particular category of severity, from mild, 
to moderate, to severe. Several studies have documented that 
the patients that populate these categories do not remain static 
within a particular category for long, being classified as mild 
on some visits and more moderate or severe at another. If 
most asthmatics are constantly evolving over time (perhaps 
related to when the last viral-induced exacerbation occurred, 
as well as the robustness of the host response), it makes it dif-
ficult during the course of a clinical trial to ascribe changes in 
symptomatology or objective parameters of disease severity 
to a particular test treatment or intervention, even when the 
trial includes a placebo arm (clearly impossible without one). 
Since spontaneous drift in disease severity is the rule and we 
have no way of randomly assigning treatments based on future 
patterns of disease, it is not surprising that most asthma trials 
require large numbers of enrollees in order to minimize the 
effects of this variability. This intrinsic within-subject vari-
ability may also render “ethical issues” of using a placebo in 
asthma trials moot, since no currently available therapy has 
been shown to alter the course of viral-induced respiratory 
disease and the effect of inhaled corticosteroid therapy on 
rate and severity of future exacerbations is modest at best.18 
Needless to say, patients with unstable disease should not be 
enrolled in placebo-control trials for obvious reasons.
Conclusion
In conclusion, it is generally accepted that a majority of 
asthma exacerbations in both children and adults are the 
result of viral URIs. These acute episodes are followed by a 
convalescent phase which can be difficult to characterize or 
predict in any given patient. The rate of and extent to which 
recovery occurs determines for the most part the asthma 
severity scores of the majority of patients. The frequency 
of viral infections should have a major role in determining 
disease severity and long-term patterns. Future research 
can productively focus on ways of characterizing airway 
response to viral injury, both in the acute and convalescent 
phases.19 Increased efforts should be directed at enhancing 
antiviral immune response in asthma and discovering effec-
tive and safe antiviral agents, with a vaccine against the 
major respiratory viral pathogens being the ultimate primary 
prevention strategy, although a humoral-immunity enhanc-
ing vaccine may prove futile because of the large number of 
HRV serotypes. A more plausible “vaccine” would enhance 
antiviral innate immunity, thus preventing viral attachment 
and/or replication.
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